Proteins That Work at the Ends of DNA Could Provide Cancer

New Post Public Reply Private Reply Replies (1) Message Board

Nov 30, 2012 at 6:42 AM

Proteins That Work at the Ends of DNA Could Provide Cancer Insight
http://www.sciencedaily.com/releases/2012/11/...152029.htm

ScienceDaily (Nov. 29, 2012) — New insights into a protein complex that regulates the very tips of chromosomes could improve methods of screening anti-cancer drugs.

Led by bioengineering professor Sua Myong, the research group's findings are published in the journal Structure.

Myong's group focused on understanding the proteins that protect and regulate telomeres, segments of repeating DNA units that cap the ends of chromosomes. Telomeres protect the important gene-coding sections of DNA from loss or damage, the genetic equivalent of aglets -- the covering at the tips of shoelaces that keep the ends of the laces from unraveling or fraying.

Telomeres play an important role in cell aging and death, since each time a cell divides, a little bit is lost from the end of the telomere. Thus, cell biologists postulate that telomere length can determine the lifespan of a cell. Cancer cells, however, have a way to get around this limitation: An enzyme called telomerase that adds length to telomeres is highly active in cancer cells. This allows cancer cells to divide in perpetuity, running amok through tissues and systems.

"Cancer researchers want to get a hold of this problem, control this indefinite lengthening of the telomeres," said Myong, who also is affiliated with the Institute for Genomic Biology at the U. of I. "A lot of the anti-cancer drugs are targeted directly to these telomeres so that they can inhibit telomerase activity. The proteins we study regulate the activity of telomerase."

Using a technique developed at Illinois that allows researchers to watch single molecules interact in real time, Myong's group determined how two proteins called POT-1 and TTP-1 bind to the telomere. POT-1 protects the fragile telomere ends from being attacked by other regulatory proteins that might mistake the end for a broken or damaged area of DNA. When POT-1 and TTP-1 work together in a complex, they promote telomerase activity, an interesting target for cancer researchers.

The group found that on its own, POT-1 binds to the folded-up telomere in distinct steps at particular points in the telomere's DNA sequence, unfolding the telomere in a stepwise manner. However, the POT-1/TTP-1 complex surprised the researchers by binding, then freely sliding back and forth along the telomere end.

"Instead of stepwise binding, what we saw was a mobile protein complex, a dynamic sliding motion," Myong said. "Somehow it was as if the static binding activity of POT-1 is completely lost -- the protein complex just slid back and forth. We were able to reproduce the data and confirm it with many different tail lengths of the telomeric DNA and we know now that the contact between POT-1 and the telomere is somehow altered when the partner protein comes and binds."

Next, the researchers will add telomerase and see how the sliding activity of the POT-1/TTP-1 complex affects telomerase activity. Myong postulates that the sliding may promote telomerase activity -- and thus telomere lengthening -- by making the end of the telomere accessible for the telomerase enzyme to bind.

"We are excited about the possibility that this kind of mobility can increase the telomerase extension activity," Myong said. "It's somehow engaging the enzyme so that it can stay bound to the DNA longer. So it must involve a direct interaction."

Ultimately, understanding the POT-1/TTP-1 complex gives drug developers a new target for anti-cancer drugs, and the assay Myong's group used to monitor the complex could offer a venue for evaluating telomere-targeting drugs.

"We want to extend our a basic science knowledge in telomere biology into causes of cancer and we hope that our assay can be useful for telomere-targeted drug screening," Myong said.

The American Cancer Society and the Human Frontier Science Research Program supported this work.

Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

The Real Cost of Cabinet Decisions: Refinish or Replace?

Uncovering the Truth Behind Cabinet Decisions When it comes to sprucing up a kitchen, most folks overlook what's hanging on their walls already: those tired old cabinets. Now, are you looking at chucking them out the window for brand-new ones, or can a fresh coat of paint breathe new life into them? Well, that's where Melvin Jones, a painting virtuoso from Lexington,...

Govee Stirs Halloween Chills with New Sarah Gellar Ad

Lighting Up Halloween the Hollywood Way When it comes to Halloween, folks go nuts driving up the thrill factor at home, and boy, has Govee nailed it this time around. They've dragged Sarah Michelle Gellar into their spooky mix, transforming homes into eerie masterpieces. And let's face it, who better than the 'Buffy the Vampire Slayer' herself to stir those spine-tingling...

Vatrer Power: Lithium Batteries Revolutionize Golf Carts

The humdrum world of golf carts just got a jolt of energy with lithium batteries entering the fray. Vatrer Power, the brain behind some nifty LiFePO4 lithium battery conversions, made some noise at this year's Golf Carting Expo & Dealer Summit in Charleston, South Carolina. Held at the North Charleston Convention Center, this trade show was the industry's premier...

Aetna's 2027 Medicare Plans: Comprehensive Outlook

Unpacking Aetna's Medicare Strategy for 2027 Look, if there's one thing you should keep tabs on, it's how Aetna isn't just coasting by in the healthcare arena. These folks are pushing forward with new options for 2027 that prove they're serious about making healthcare not just accessible, but affordable across the board. Aetna, backed by CVS Health (NYSE: CVS), is making...

Ractigen's Breakthrough in DMD: RNA Activates Utrophin

Ractigen's New Fight Against Duchenne: A Personal Take When it comes to biotech advancements, I've seen enough breakthroughs to not get swayed easily. But Ractigen Therapeutics presenting their first-in-human data on RNA activation for Duchenne Muscular Dystrophy (DMD) kind of demands your attention. Folks, they're talking about a potential shift in handling this brutal...

Venice's Climate Challenge: Rising Seas, Sinking Lands

Sea Rise Isn’t Just a Statistics Problem The ordeal of rising seas isn't just about staring at numbers in some spreadsheet, it's a real-world gut punch that's knocking at Venice's door. This city, known for its stunning architecture and winding canals, now serves as the poster child for what happens when Mother Nature and human errors leave a place on the brink of...

Kal Plastics Showcases at Design-2-Part Expo

Kal Plastics Steps into the Limelight There's a buzz in the air, and it's all about Kal Plastics getting ready to strut their stuff at the Southern California Design-2-Part Show. Now, most folks probably don't spend their nights dreaming about thermoforming and pressure forming, but these guys sure make a case for it. They’ve got their eyes on impressing the crowd with...

Honeywell's Supply Line Snags Bait Class Action Risk

Stepping into the chaos of the stock market sometimes feels like opening Pandora's box—just when you think you've seen it all, something new tumbles out. This time around, it's Honeywell Aerospace (NasdaqGS: HONA) playing catch with hot coals, and a burning class-action lawsuit smolders in the air. Deadline Looms for Investors in Class Action Heads up, folks! If you've...

Trading Platforms Poised for Billions by 2031

Forecasts and Fierce Digital Landscapes Just when you thought the online trading realm was getting saturated, the numbers are making it clear: there’s still room for growth—even explosive growth. The online trading platform market is eyeing a hike, jumping from a $11.65 billion valuation in 2025 to a projected $18.18 billion by 2031, according to Mordor Intelligence....